The PennZone

  • Home
  • Books
  • Entertainment
  • Marketing
  • Non-profit
  • Music
  • Education
  • Health
  • Business

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • L2 Aviation Welcomes Jason Marshall as Vice President of Sales and Business Development
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • YWCA Hanover to Host 7th Annual EMERGE Women's Conference
  • Las Vegas Attorney Thomas Boley Publishes Free Plain-English Guide to 100 Nevada Criminal Laws, in English and Spanish
  • Is Your Home Buyer REALLY Qualified?
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
  • NYC Big Book Award Celebrates 10th Anniversary with Announcement of 2026 Winners
  • Birch Run Psychological Services Launches Updated Online Therapy Website
  • Perfexion Inc. Recognized in the Philadelphia Business Journal's 2026 Branding, Marketing and Media Services List
  • Regional Magazines Shine at IRMA Awards
  • Matt Zavala of Zavala Law, PC Selected to the 2027 Super Lawyers List
  • Sawgrass Ford President Attributes Dealerships Success to Long-Term Employees
  • New Children's Book "Frolly Found a Dolly in the Park" Celebrates Empathy and the Joy of Help
  • Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
  • Can Government Operate Better Through Innovation?
  • Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter

Popular on PennZone

  • Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing - 228
  • Easwe Lightweight Electric Wheelchair Collection with Travel-Focused Mobility Solutions - 200
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 193
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 176
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration - 150
  • INAD Warriors' 4th Annual "Dancing with the INAD Stars" Gala - 144
  • Michael Fischer, President and CEO of Client 1st Financial, Named to LVB 300 - 128
  • Brévant Guide Launches New National Restaurant Guide Across Canada - 117
  • Calling all healthcare process experts: Share your ideas at #HSPI2027 in Orlando - 114
  • VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8 - 105

Similar on PennZone

  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us